{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-001673","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2025-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.159478+00:00","generated_at":"2026-05-22T01:46:24.041600+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Entera Bio Q1 net loss $2.6M ($0.06/sh); cash runway to mid-Q3 2026; pipeline advances","bullets":["Net loss of $2.6M ($0.06 per share) for Q1 2025 vs $2.0M ($0.05) in Q1 2024; operating expenses $2.6M.","Cash and equivalents $20.6M as of Mar 31, 2025; expects to fund operations through mid-Q3 2026.","EB613 (oral PTH) bone data presented at WCO-IOF-ESCEO Apr 2025; Next Gen EB613 Phase 1 planned H2 2025.","Collaboration with OPKO for oral GLP-1/Glucagon program; IND filing planned late 2025/early 2026.","Appointed Cherin Smith as EVP Clinical Ops (Mar) and Leslie Gautam as CBO (May 2025)."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-001673","json":"https://secwatch.observer/filing/0001178913-25-001673.json","markdown":"https://secwatch.observer/filing/0001178913-25-001673.md","text":"https://secwatch.observer/filing/0001178913-25-001673.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891325001673/0001178913-25-001673-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891325001673/zk2533149.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:46:24.041600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}